A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens
- To determine the correlation between c-Met expression, mutation and amplification, with
stage and overall survival in patients with adenocarcinoma (AC) of the lung.
- To determine the correlation with epithelial mesenchymal transition (EMT), EGFR
mutations and expression, Kras mutations, p53 mutations, c-CBL protein expression,
mutation, loss of heterozygosity (LOH), DUB3 expression & regulation, and ALK
translocation, with respect to survival.
- To determine the correlation with circulating c-Met and HGF in AC and evaluate
prognostic implications of circulating markers in AC of lung.
- To determine (when available) levels of circulating Met and HGF in serum before and
OUTLINE: This is a multicenter study.
Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for
mutation analysis of c-Met, EGFR, and K-ras. DNA is examined by PCR, followed by agarose gel
electrophoresis; gene amplification of c-Met is examined by real time quantitative PCR;
met/HF protein in serum is examined by ELISA; and c-Met, EGFR, p53, c-CBL, DUB3 enzyme, and
ALK, and epithelial mesenchymal transition examined by IHC.
Correlation of c-Met expression and stage and overall survival
Ravi Salgia, MD, PhD
University of Chicago
United States: Federal Government